RANZCR response to MSAC Application 1643

Download pdf - 226.9KB

Response to MSAC Application 1643 – Two testing options for determining eligibility for access to Pharmaceutical Benefits Schedule (PBS) subsidised aducanumab in patients with early stage Alzheimer’s disease.

RANZCR provided written feedback to the Medical Services Advisory Committee (MSAC) to support MSAC Application 1643 – Two testing options for determining eligibility for access to Pharmaceutical Benefits Schedule (PBS) subsidised aducanumab in patients with early stage Alzheimer’s disease.

RANZCR broadly supports the use of Aβ PET for the clinical assessment of Alzheimer’s disease.

July 2021